doi:10.1210/edrv-14-1-107 [2] Hu S, Rayman MP
Safety Profile Across all six human trials and the extensive preclinical work, the safety picture is quite clean: No serious adverse events attributed to the compound No effect on IGF-1 No impairment of glucose tolerance or insulin sensitivity No genotoxic activity Most common side effects: mild injection site irritation, occasional headache or fatigue all transient This is genuinely one of the better-characterized peptides from a safety standpoint, largely because it actually went through a formal development process with proper clinical oversight
NAD+ & cellular metabolism Explored in cell research on how NNMT inhibition affects NAD+ and SAM levels investigational, animal and in-vitro only
Missed doses interrupt the steady buildup that pills depend on, and some high-dose tablets are large and hard to swallow
It works by inhibiting the NNMT enzyme, which is associated with fat storage, insulin resistance, and reduced cellular energy
